Insmed reported $132.91M in Stock for its fiscal quarter ending in March of 2026.





Stock Change Date
BioMarin Pharmaceutical USD 1.27B 25.66M Mar/2026
Gilead Sciences USD 1.91B 140M Mar/2026
Heron Therapeutics USD 54.57M 2.33M Dec/2022
Insmed USD 132.91M 841K Mar/2026
Novartis USD 6.29B 135M Mar/2026
Regeneron Pharmaceuticals USD 3.1B 97.2M Mar/2026
Sarepta Therapeutics USD 1B 86.37M Mar/2026
Ultragenyx Pharmaceutical USD 55M 3M Mar/2026
Vertex Pharmaceuticals USD 1.77B 79.9M Mar/2026